Overview

A Study of Golimumab in Participants With Active Psoriatic Arthritis

Status:
Completed
Trial end date:
2017-03-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active psoriatic arthritis (a chronic inflammatory arthritis that is associated with psoriasis).
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Antibodies, Monoclonal
Golimumab